Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049725 · ClinicalTrials.gov registry record · Phase 2
Daclizumab to Treat Chronic Immune Thrombocytopenia
A Phase 2 study of Thrombocytopenia, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00049725: Completed Phase 2 study of Thrombocytopenia, sponsored by National Institutes of Health Clinical Center (CC).
NCT00049725 is a Phase 2 study of Thrombocytopenia that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 24 participants, below the 311-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049725, a Phase 2 study of Thrombocytopenia, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of the drug daclizumab for treating patients with chronic immune thrombocytopenia (ITP), a disease in which the immune system destroys platelets (blood cells involved in the clotting process). Patients with ITP have abnormal bruising and bleeding; severe disease can be life-threatening. For many patients, standard drug treatments are not effective, and many of the drugs used may have significant side effects with long-term use. Daclizumab is a genetically engineered antibody that suppresses the immune system and has been used primarily to prevent rejection in patients who have had organ transplants. Daclizumab has fewer side effects than other immune suppressant drugs. Patients with ITP 18 years of age or older who have platelet counts less than 30,000/microliter and have not responded to prednisone treatment may be eligible for this study. Candidates will be screened with a medical history, physical examination, and blood tests. Participants will have a 15-minute infusion of daclizumab every 2 weeks for five doses. They will be seen by a physician at least once every 2 weeks while receiving the drug and then at weeks 12, 20, and 32 of the study. Blood will be drawn at the 4- and 8-week visits during treatment for diagnostic tests, and at each follow-up visit after treatment to assess the response to therapy. Patients who respond well to treatment will have their pre-study immunosuppressive medicines tapered gradually one at a time starting with the 1-month follow-up visit. If their platelet count falls to pre-treatment levels at any time during the tapering, the dose reduction will stop and pre-study medications will be re-started, if necessary.
Conditions Studied
Interventions
- DRUG Daclizumab
Study Locations (1)
Maryland
- Warren G. Magnuson Clinical Center (CC) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00049725 record still lists
NCT00049725 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 311-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Daclizumab is the first listed.
NCT00049725 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00049725 about?
NCT00049725 is a clinical study titled "Daclizumab to Treat Chronic Immune Thrombocytopenia". This study will evaluate the effectiveness of the drug daclizumab for treating patients with chronic immune thrombocytopenia (ITP), a disease in which the immune system destroys platelets (blood cells involved in the clotting process). Patients with ITP have abnormal bruising and bleeding; severe di...
What is the current status of trial NCT00049725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2002-11. Estimated completion is 2004-12.
What conditions does trial NCT00049725 study?
This clinical trial studies the following conditions: Thrombocytopenia.
What interventions are being tested in trial NCT00049725?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00049725?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00049725 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00049725's enrollment target sits among peer trials
24 15th of 20 higher than 5 of 20 other Thrombocytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
COMPLETED · Phase 2
-
Eltrombopag for Post Transplant Thrombocytopenia
COMPLETED · Phase 2
-
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia